skip to main content

Recurrent dabigatran-associated major bleeding due to rebound anticoagulation in acute kidney injury — ABIM Bo

Instant feedback + full explanation. One question, done properly.

HardBleedingRecurrent dabigatran-associated major bleeding due to rebound anticoagulation in acute kidney injuryABIM Board

A 79-year-old man with atrial fibrillation takes dabigatran, 150 mg twice daily. His baseline creatinine concentration is 1.2 mg/dL. He is admitted with septic shock and oliguric acute kidney injury; creatinine is 5.8 mg/dL. Twelve hours after his last dabigatran dose, he develops hypotension and a spontaneous retroperitoneal hematoma. The hemoglobin concentration decreases from 11.4 to 7.6 g/dL, and the diluted thrombin time exceeds the assay limit. Dabigatran is discontinued, idarucizumab 5 g is administered intravenously, and angiographic embolization achieves source control. The diluted thrombin time initially normalizes. Sixteen hours later, hypotension recurs and the hemoglobin concentration decreases from 9.1 to 7.8 g/dL. CT shows expansion of the hematoma without a focal arterial source amenable to repeat embolization. The platelet count is 174,000/mm³, fibrinogen is 390 mg/dL, INR is 1.2, and the diluted thrombin time is again markedly prolonged. The plasma dabigatran concentration is 280 ng/mL. Which of the following is the most appropriate immediate anticoagulant-reversal intervention?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Administer a second dose of intravenous idarucizumab, 5 g

This patient has recurrent life-threatening bleeding with objective reappearance of dabigatran activity after initially successful reversal. Severe acute kidney injury markedly reduces dabigatran clearance; after idarucizumab concentrations decline, redistribution of accumulated dabigatran into plasma can produce rebound anticoagulation. Recurrent bleeding together with a markedly prolonged diluted thrombin time and measurable dabigatran concentration supports an immediate second 5-g dose of idarucizumab. Hemodialysis may subsequently assist drug removal in severe renal failure, but it is not the preferred sole immediate intervention in an unstable patient when the specific antidote is available. Phytonadione reverses vitamin K antagonists and has no effect on dabigatran. Andexanet alfa reverses factor Xa inhibitors such as apixaban and rivaroxaban, not direct thrombin inhibitors. Four-factor prothrombin complex concentrate is an alternative nonspecific hemostatic therapy when idarucizumab is unavailable, but it is not preferred when recurrent dabigatran activity is documented and repeat specific reversal is possible. Hemodialysis can remove a substantial proportion of circulating dabigatran and is particularly relevant in renal failure or persistent rebound; however, its onset is less immediate, vascular access may be hazardous during active anticoagulation, and it should not replace repeat idarucizumab for current life-threatening hemorrhage.

Reference: ACC Consensus on Management of Anticoagulant-Related Bleeding (July 14, 2020) — https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/07/10/11/26/2020-ACC-Expert-Consensus-Decision-Pathway-on-Bleeding 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants (2020) — https://cvquality.acc.org/docs/default-source/initiatives/reduce-the-risk-pci-bleed/2020-acc-expert-consensus-decision-pathway-on-management-of-bleeding-in-patients-on-oral-anticoagulants.pdf Idarucizumab for Dabigatran Reversal—Full Cohort Analysis (August 3, 2017) — https://www.nejm.org/doi/full/10.1056/NEJMoa1707278